Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Evaluation of Efficacy and Safety of Pazopanib Combined with TGI/CIV(nab⁃Paclitaxel+ Gemcitabine + Ifosfamide/cyclophosphamide +Irinotecan + Vinorelbine) in the Treatment for Children or Adolescents with Recurrent/refractory Rhabdomyosarcoma--an Open-label, Single-arm, Single-cente,phase II Clinical Trial

To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.

Study Overview

• Status: Recruiting
• Conditions: Rhabdomyosarcoma, Recurrent, Refractory
• Intervention / Treatment: Drug: pazopanib; Drug: TGI chemotherapy; Drug: CIV chemotherapy

• Study Type: Interventional
• Enrollment (Estimated): 38
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Shuai Man, Doctor; Phone Number: 0086-18822026105; Email: shuai2328@163.com

Study Locations

• China
  • Shandong
    • Jinan, Shandong, China, China,250117
      • Recruiting
      • No. 440 Jiyan Road, Jinan City, Shandong Province
      • Contact: Shandong Cancer Hospital; Phone Number: +86 0531 67626786; Email: shuai2328@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

1. Histologically or cytologically confirmed rhabdomyosarcoma (RMS).

2. Patients diagnosed with recurrent/refractory RMS based on clinical diagnostic criteria. Recurrence is defined as disease recurrence confirmed after achieving complete remission and completing at least one line of standard treatment; refractory is defined as disease progression as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) after at least four cycles of first-line chemotherapy.

   First-line standard treatment can refer to the "Diagnosis and Treatment Guidelines for Rhabdomyosarcoma in Children and Adolescents (2019 Edition)".

3. Patients must have measurable lesions as per RECIST 1.1 criteria.
4. Age ≥ 2 years and ≤ 18 years, with no gender restrictions.
5. Karnofsky Performance Scale (KPS) score of 70-100% (> 12 years) or Lansky Performance Scale score of 70-100% (≤ 12 years).
6. Expected survival time ≥ 12 weeks.
7. Before initiating any project-related procedures, the parents/guardians of the child or adolescent subjects must be able to understand, consent, and sign the informed consent form (ICF) and applicable assent form; the subjects must be able to express consent with the consent of their parents/guardians (if applicable).
8. Adequate organ and bone marrow function, defined as follows:

Bone marrow function:

1. Absolute neutrophil count (ANC) ≥ 1.5×109/L (≥ 0.5×109/L if bone marrow metastasis)
2. Platelet count ≥ 100×109/L (≥ 75×109/L if bone marrow metastasis) Hb ≥ 65 g/L (blood transfusion is allowed)
3. Hematopoietic growth factors: Treatment should be initiated at least 14 days after the last administration of long-acting growth factors or 1 day after the last administration of short-acting growth factors. renal function

1) Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) 2) If serum creatinine > 1.5 ULN, creatinine clearance rate > 70 ml/min/1.73 m² Liver function

1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastasis)
2. Total bilirubin ≤ 1.5 times ULN Cardiac function

1) Echocardiography LVEF ≥ 50%; 2) No severe cardiac rhythm or conduction abnormalities on electrocardiogram.

Exclusion criteria:

1. Received any of the following treatments within 2 weeks before treatment: radiotherapy, chemotherapy, or molecular targeted therapy for tumors; other investigational drugs; or live attenuated vaccines.
2. Patients who have received anti-angiogenic targeted drugs such as apatinib, pazopanib, sunitinib, sorafenib, bevacizumab, imatinib, crizotinib, famitinib, anlotinib, regorafenib, endostatin, etc. within the past 3 months.
3. Central nervous system metastasis.
4. A history of thrombosis within 3 months before enrollment and anticoagulation treatment for less than 6 weeks.
5. Known bleeding tendency, significant clinical bleeding symptoms within 3 months before treatment or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ or above, vasculitis, etc.; or thrombotic events within 6 months before treatment, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.; or need long-term anticoagulation treatment with warfarin or heparin, or need long-term antiplatelet treatment (aspirin ≥ 300 mg/day or clopidogrel ≥ 75 mg/day).
6. Uncontrolled hypertension and proteinuria in the recent period. And cannot be well controlled by antihypertensive drugs (infants > 100/60 mmHg, preschool children (< 6 years old) > 110/70 mmHg, school-age children (6-12 years old) > 120/80 mmHg, adolescents and adults > 140/90 mmHg).
7. Use of antiepileptic drugs.
8. Long-term unhealed wounds, ulcers or fractures, major surgery within 28 days before enrollment or minor surgery within 7 days, abdominal fistula, gastrointestinal perforation.
9. Uncontrolled severe infection.
10. The presence of active heart disease within 6 months before treatment, including myocardial infarction, severe/unstable angina, etc. Poorly controlled arrhythmias with left ventricular ejection fraction < 50% on echocardiography (including QTcF intervals >450 ms in men and >470 ms in women).
11. Any other malignancy was diagnosed within 3 years before treatment.
12. Known allergy to the study drug or any of its excipient.
13. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B surface antigen positive and HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody positive and HCV-RNA above the detection limit of the assay).
14. According to the judgment of the researchers, patients with large tumors, easy to rupture and bleeding, and bleeding caused by tumor retraction are at high risk.
15. Concomitant medical conditions (e.g., poorly controlled hypertension, severe diabetes, neurological or psychiatric conditions, etc.) or any other condition that, in the investigator's judgment, could seriously endanger the safety of the subject, confound the study results, or interfere with the completion of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Experimental group; The participant take pazopanib once daily orally in combination with a total of 2 cycles(6 weeks) of TGI chemotherapy(nab⁃Paclitaxel+ gemcitabine + ifosfamide)/CIV(cyclophosphamide +Irinotecan + vinorelbine).Each cycle of TGI/CIV chemotherapy will last for 3 weeks, TGI will be given in cycle 1 and CIV will be given cycle 2 . At week 6, the participant will have scans and tests to reevaluate the tumor's response to the treatment. The participant will receive an additional 6 weeks (2 cycles) of the same chemotherapy in the absence of disease progression or unacceptable toxicity. After 4 cycles of chemotherapy, The investigator will re-evaluate the tumor again at week 12 and the patient will undergo other treatments(chemotherapy, radiation, surgery, etc.), but will be closely watched for any signs of tumor recurrence or progression.

Drug: pazopanib; Given PO The dosage will be determined according to the participant's body surface area, with body surface area less than 0.75, 1 tablet, and 2 tablets for body surface area greater than 1. 0.75-1,1.5 tablets.; Drug: TGI chemotherapy; TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide); Drug: CIV chemotherapy; CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate(ORR)	Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1	Up to 4 cycles of chemotherapy (each cycle is 21 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Disease control rate (DCR)	Refers to the percentage of patients with confirmed complete response, partial response, and disease stability in patients with evaluable efficacy	Up to 4 cycles of chemotherapy (each cycle is 21 days)
Incidence of adverse events	Use NCI-CTCAE version 5.0 for classification and grading	Up to 4 cycles of chemotherapy (each cycle is 21 days)

Collaborators and Investigators

• Sponsor: Shandong Cancer Hospital and Institute
• Investigators: Study Chair: Jingfu Wang, MD, Shandong Cancer Hospital and Institute

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2025
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: February 3, 2025
• First Submitted That Met QC Criteria: February 7, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 7, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: pediatric; rhabdomyosarcoma
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease Attributes; Neoplasms by Histologic Type; Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms, Muscle Tissue; Myosarcoma; Recurrence; Rhabdomyosarcoma
• Other Study ID Numbers: SDZLEC2024-413-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No